einstein (São Paulo). 01/Dec/2013;11(4):492-4.

Retention rates of infliximab and tocilizumab during a 3-year period in a Brazilian hospital

Ricardo Prado Golmia, Morton Aaron Scheinberg

DOI: 10.1590/S1679-45082013000400015

Objective:
To compare the efficacy and the period of use of tocilizumab and infliximab during treatment of rheumatoid arthritis patients.
METHODS:
The period of use of two biologics with different mechanisms of action were compared in treatment of rheumatoid arthritis patients. RES: ULTS: Both medications showed efficacy, but the period of use with no loss of efficacy was longer in patients receiving tocilizumab when compared to infliximab.
CONCLUSION:
Tocilizumab maintains a period of use significantly longer as compared with infliximab in patients with rheumatoid arthritis treated at a single organization.

Retention rates of infliximab and tocilizumab during a 3-year period in a Brazilian hospital

Comments